PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA

HCR · Health Issues

340B drug discount program; drug pricing; importation of biopharmaceuticals; direct-to-consumer (DTC) advertising; transparency; international pharmaceutical supply chain; antimicrobial resistance; insulin price cap; PBM reform; TRICARE Pharmacy Program (FY2026 National Defense Authorization Act); Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; Inflation Reduction Act of 2022 (P.L.117-169) implementation; S.891, Bipartisan Health Care Act; S.527, Prescription Pricing for the People Act of 2025; S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act; S.1097, Interagency Patent Coordination and Improvement Act of 2025; S.1095, Stop STALLING Act; S.1096, Preserve Access to Affordable Generics and Biosimilars Act.

Literal federal measure citations: S.891, S.527, S.1040, S.1041, S.1097, S.1095, S.1096

MMM · Medicare/Medicaid

General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; noninterference; drug pricing; Valued-Based Payments; Inflation Reduction Act of 2022 (P.L.117-169) implementation.

BUD · Budget/Appropriations

H.R.1968, Full-Year Continuing Appropriations and Extensions Act, 2025 (P.L.119-4); H.Con.Res.14, FY2025 Budget Resolution; FY2025 Budget Reconciliation Process; all bio-pharmaceutical related provisions.

Literal federal measure citations: H.R.1968, H.Con.Res.14

CPT · Copyright/Patent/Trademark

Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues.

TRD · Trade (domestic/foreign)

Issues related to pharmaceutical IP, supply chain, and tariffs.